Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen To Study Aranesp Anemia Indication In Heart Failure Patients

Executive Summary

Amgen is considering an appropriate design for a Phase III trial evaluating Aranesp (darbepoetin alfa) to treat anemia in patients with congestive heart failure

You may also be interested in...



Amgen Looks To U.S. Contracting Strategies To Head Off European Biosimilars

Amgen is bringing U.S. contracting strategies to Europe as part of its efforts to stave off competition from biosimilars, Exec VP-Commercial Operations George Morrow said during the firm's recent annual business review

Amgen Looks To U.S. Contracting Strategies To Head Off European Biosimilars

Amgen is bringing U.S. contracting strategies to Europe as part of its efforts to stave off competition from biosimilars, Exec VP-Commercial Operations George Morrow said during the firm's recent annual business review

Procrit Shows Benefits Over Aranesp In Anemia Patient Study

Cancer patients with chemotherapy-induced anemia who are treated with Procrit (epoetin alfa) experience a higher increase in hemoglobin levels than those treated with Aranesp (darbepoetin alfa), according to a study in the September issue of The Oncologist.

Related Content

Topics

UsernamePublicRestriction

Register

PS046106

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel